Details of the Drug Combination

General Information of Drug Combination (ID: DCAV5CD)

Drug Combination Name

ATI-17000 JQ1

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

ATI-17000 DMZJVR5

JQ1 DM3XQDH

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 20.919

Bliss Independence Score: 25.865

Loewe Additivity Score: 12.344

LHighest Single Agent (HSA) Score: 13.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of ATI-17000

Disease Entry	ICD 11	Status	REF
Irritable bowel syndrome	DD91.0	Preclinical	[2]

ATI-17000 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Nociceptin receptor (OPRL1)	TTNT7K8	OPRX_HUMAN	Antagonist	[4]
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Antagonist	[2]
------------------------------------------------------------------------------------

Indication(s) of JQ1

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]

JQ1 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HUMAN bromodomain-containing protein 2 (BRD2)	TTNISW6	BRD2_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
3	Uncovering the Role of BRD2 in COVID-19. 2020-03-19
4	Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.